卢旺达南部疟原虫基因多态性变化模式。
Changing Pattern of Plasmodium falciparum Gene Polymorphisms in Southern Rwanda.
机构信息
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Tropical Medicine and International Health, Berlin, Germany.
University Teaching Hospital of Butare, Huye, Rwanda.
出版信息
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0090121. doi: 10.1128/AAC.00901-21.
Abstract
Plasmodium falciparum gene () polymorphisms associate with altered antimalarial susceptibility. Between 2010 and 2018/2019, we observed that the prevalence of the wild-type allele N86 and the wild-type combination NYD increased 10-fold (4% versus 40%) and more than 2-fold (18% versus 44%), respectively. Haplotypes other than NYD or NFD declined by up to >90%. Our molecular data suggest the pattern shifted toward one associated with artemether-lumefantrine resistance.
摘要
恶性疟原虫基因（）多态性与抗疟药物敏感性改变相关。在 2010 年至 2018/2019 年期间，我们观察到野生型等位基因 N86 和野生型组合 NYD 的流行率增加了 10 倍（4%对 40%）和两倍以上（18%对 44%）。除 NYD 或 NFD 以外的单倍型下降了高达>90%。我们的分子数据表明，这种模式向与青蒿琥酯-咯萘啶耐药相关的模式转变。
相似文献
1
Changing Pattern of Plasmodium falciparum Gene Polymorphisms in Southern Rwanda.卢旺达南部疟原虫基因多态性变化模式。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0090121. doi: 10.1128/AAC.00901-21.
2
Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.2016 年至 2021 年坦桑尼亚大陆地区与青蒿素类药物耐药性和降低对青蒿琥酯敏感性相关的恶性疟原虫分子标志物趋势。
Malar J. 2024 Mar 9;23(1):71. doi: 10.1186/s12936-024-04896-0.
3
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.印度东北部国际边界地区无并发症恶性疟原虫疟疾病例 PfMDR1 多态性的时空分布。
Infect Genet Evol. 2018 Sep;63:285-290. doi: 10.1016/j.meegid.2018.05.025. Epub 2018 May 26.
4
Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.2015 年安哥拉三省无并发症恶性疟原虫感染患者中青蒿素和咯萘啶耐药相关分子标志物的流行情况。
Malar J. 2018 Feb 20;17(1):84. doi: 10.1186/s12936-018-2233-5.
5
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.在利比里亚，用青蒿琥酯-阿莫地喹固定剂量复方或蒿甲醚-本芴醇治疗后恶性疟原虫pfcrt和pfmdr1基因多态性的选择
Malar J. 2016 Sep 5;15(1):452. doi: 10.1186/s12936-016-1503-3.
6
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.疟原虫氯喹耐药转运体和多药耐药基因 1 多态性：影响青蒿琥酯-咯萘啶和青蒿琥酯-阿莫地喹治疗恶性疟原虫疟疾后治疗结局的寄生虫危险因素。
Am J Trop Med Hyg. 2014 Oct;91(4):833-843. doi: 10.4269/ajtmh.14-0031. Epub 2014 Jul 21.
7
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia.柬埔寨恶性疟原虫中Pfmdr1基因拷贝数与青蒿素衍生物联合疗法失败情况
Malar J. 2009 Jan 12;8:11. doi: 10.1186/1475-2875-8-11.
8
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.在卢旺达，恶性疟原虫kelch13 R561H 基因型与寄生虫清除延迟的关联：一项开放标签、单臂、多中心、治疗效果研究。
Lancet Infect Dis. 2021 Aug;21(8):1120-1128. doi: 10.1016/S1473-3099(21)00142-0. Epub 2021 Apr 14.
9
Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine.在法国城市加蓬的班古替换氯喹为青蒿琥酯-咯萘啶和青蒿琥酯-甲氟喹后，恶性疟原虫 Pfmdr1 86N 基因型的流行率增加。
Infect Genet Evol. 2011 Mar;11(2):512-7. doi: 10.1016/j.meegid.2011.01.003. Epub 2011 Jan 17.
10
Sustained Susceptibility of Plasmodium falciparum to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia.冈比亚恶性疟原虫对青蒿素衍生物持续敏感，但对青蒿素联合疗法中的喹啉类药物耐受性增加。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.00759-17. Print 2017 Dec.
引用本文的文献
1
artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024.2024年乌干达西部福特portal的青蒿素部分抗性标志物
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0175524. doi: 10.1128/aac.01755-24. Epub 2025 Apr 23.
2
Escalating marker prevalence indicative of artemisinin resistance in southern Rwanda.卢旺达南部青蒿素耐药标志物流行率上升。
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0129923. doi: 10.1128/aac.01299-23. Epub 2023 Dec 11.
3
In Vitro Confirmation of Artemisinin Resistance in Plasmodium falciparum from Patient Isolates, Southern Rwanda, 2019.2019 年，来自卢旺达南部患者分离株的疟原虫青蒿素耐药性的体外确认。
Emerg Infect Dis. 2022 Apr;28(4):852-855. doi: 10.3201/eid2804.212269.
本文引用的文献
1
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.在卢旺达，恶性疟原虫kelch13 R561H 基因型与寄生虫清除延迟的关联：一项开放标签、单臂、多中心、治疗效果研究。
Lancet Infect Dis. 2021 Aug;21(8):1120-1128. doi: 10.1016/S1473-3099(21)00142-0. Epub 2021 Apr 14.
2
Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda.卢旺达南部疟原虫 Kelch13 多态性增加。
Emerg Infect Dis. 2021 Jan;27(1):294-296. doi: 10.3201/eid2701.203527.
3
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.卢旺达青蒿素耐药恶性疟原虫kelch13 R561H 突变体寄生虫的体外出现和克隆扩增。
Nat Med. 2020 Oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. Epub 2020 Aug 3.
4
Emerging implications of policies on malaria treatment: genetic changes in the gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa.疟疾治疗政策的新影响：非洲影响对蒿甲醚-本芴醇和青蒿琥酯-阿莫地喹敏感性的基因中的遗传变化。
BMJ Glob Health. 2018 Oct 19;3(5):e000999. doi: 10.1136/bmjgh-2018-000999. eCollection 2018.
5
Expanding home-based management of malaria to all age groups in Rwanda: analysis of acceptability and facility-level time-series data.在卢旺达将疟疾的家庭管理扩大到所有年龄段：可接受性和设施层面时间序列数据分析。
Trans R Soc Trop Med Hyg. 2018 Nov 1;112(11):513-521. doi: 10.1093/trstmh/try093.
6
The threat of antimalarial drug resistance.抗疟药物耐药性的威胁。
Trop Dis Travel Med Vaccines. 2016 Jul 7;2:10. doi: 10.1186/s40794-016-0027-8. eCollection 2016.
7
Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Drug Sensitivity-Associated Haplotypes in Uganda.蒿甲醚-本芴醇和双氢青蒿素-哌喹对乌干达与药物敏感性相关的单倍型施加反向选择压力。
Open Forum Infect Dis. 2016 Oct 25;4(1):ofw229. doi: 10.1093/ofid/ofw229. eCollection 2017 Winter.
8
Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.全球普遍存在的 PfMDR1 突变可调节恶性疟原虫对基于青蒿素的联合疗法的敏感性。
Nat Commun. 2016 May 18;7:11553. doi: 10.1038/ncomms11553.
9
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.抗疟治疗和化学预防对从乌干达儿童分离出的疟原虫药物敏感性的影响。
Antimicrob Agents Chemother. 2015;59(6):3018-30. doi: 10.1128/AAC.05141-14. Epub 2015 Mar 9.
10
High prevalence of pfmdr1 N86Y and Y184F mutations in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea.赤道几内亚比奥科岛恶性疟原虫分离株中pfmdr1基因N86Y和Y184F突变的高流行率。
Pathog Glob Health. 2014 Oct;108(7):339-43. doi: 10.1179/2047773214Y.0000000158. Epub 2014 Oct 27.
Zotero 插件